Skip to main content
SearchLoginLogin or Signup

Reviews of "Prophylactic treatment of Glycyrrhiza glabra mitigates COVID-19 pathology through inhibition of pro-inflammatory cytokines in the hamster model and NETosis"

Reviewers: Robbert Boudewijns (University of Maryland ) | 📗📗📗📗◻️ • Neeraj Kumar Sethiya (DIT University) | 📗📗📗📗◻️

Published onJun 24, 2022
Reviews of "Prophylactic treatment of Glycyrrhiza glabra mitigates COVID-19 pathology through inhibition of pro-inflammatory cytokines in the hamster model and NETosis"
key-enterThis Pub is a Review of
Prophylactic treatment of <i>Glycyrrhiza glabra</i> mitigates COVID-19 pathology through inhibition of pro-inflammatory cytokines in the hamster model and NETosis
Description

AbstractSevere coronavirus disease (COVID-19) is accompanied with acute respiratory distress syndrome & pulmonary pathology, and is presented mostly with inflammatory cytokine release, dysregulated immune response, skewed neutrophil/ lymphocyte ratio, and hypercoagulable state. Though vaccinations have proved effective in reducing the COVID-19 related mortality, the limitation of use of vaccine against immunocompromised, comorbidity, and emerging variants remains a concern. In the current study we investigate for the first-time the efficacy of Glycyrrhiza glabra (GG) extract, a potent immunomodulator, against SARS-CoV-2 infection in hamsters. Prophylactic treatment with GG showed protection against loss in body weight and 35-40% decrease in lung viral load along with reduced lung pathology in the hamster model. Remarkably, GG reduced the mRNA expression of pro-inflammatory cytokines and Plasminogen activator inhibito-1 (PAI-1). In-vitro, GG acted as potent immunomodulator by reducing Th2 and Th17 differentiation and IL-4 and IL-17A cytokine production. In addition, GG also showed robust potential to suppress ROS, mtROS and NETs generation in a concentration dependent manner in both human polymorphonuclear neutrophils (PMNs) and murine bone marrow derived neutrophils (BMDNs). Taken together, we provide evidence for the protective efficacy of GG against COVID-19 and its putative mechanistic insight, which might be developed as a future immunomodulatory approach against various pathologies with high cytokine production, aberrant neutrophil activation including coronavirus infection.

To read the original manuscript, click the link above.

Summary of Reviews: This preprint demonstrates the use of Glycyrrhiza glabra for mitigation of COVID-19 pathology in hamsters. Reviewers find the study reliable, but highlight the need to extend the study to a clinically relevant setting, and pinpoint the exact GG extract ingredients responsible.

Reviewer 1 (Robbert Boudewijns) | 📗📗📗📗◻️

Reviewer 2 (Neeraj Kumar Sethiya) | 📗📗📗📗◻️

RR:C19 Strength of Evidence Scale Key

📕 ◻️◻️◻️◻️ = Misleading

📙📙 ◻️◻️◻️ = Not Informative

📒📒📒 ◻️◻️ = Potentially Informative

📗📗📗📗◻️ = Reliable

📘📘📘📘📘 = Strong

To read the reviews, click the links below.

Comments
0
comment

No comments here

Why not start the discussion?